Nothing Special   »   [go: up one dir, main page]

CN102329315A - Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof - Google Patents

Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof Download PDF

Info

Publication number
CN102329315A
CN102329315A CN201110207280A CN201110207280A CN102329315A CN 102329315 A CN102329315 A CN 102329315A CN 201110207280 A CN201110207280 A CN 201110207280A CN 201110207280 A CN201110207280 A CN 201110207280A CN 102329315 A CN102329315 A CN 102329315A
Authority
CN
China
Prior art keywords
compound
acid
tetramethyleneimine
carboxylic acid
aminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201110207280A
Other languages
Chinese (zh)
Inventor
郭慧元
刘明亮
吕凯
冯连顺
胡锦生
吴金韦
王哲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Biotechnology of CAMS
Zhejiang Starry Pharmaceutical Co Ltd
Original Assignee
Institute of Medicinal Biotechnology of CAMS
Zhejiang Starry Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Biotechnology of CAMS, Zhejiang Starry Pharmaceutical Co Ltd filed Critical Institute of Medicinal Biotechnology of CAMS
Priority to CN201110207280A priority Critical patent/CN102329315A/en
Publication of CN102329315A publication Critical patent/CN102329315A/en
Pending legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides a fluoro methoxyimino-substituted nalidixic carboxylic acid compound and a preparation method thereof as well as an antibacterial drug composition as shown in a formula (I). The structure of a compound or medicinal salt and hydrate thereof as shown in the formula (I) is as follows in the specification.

Description

Contain substituted naphthyridon carboxylic acid compounds of fluorine methoxyimino and preparation method thereof
Technical field
The invention belongs to the medical chemistry field, relate to and have active naphthyridon carboxylic acid verivate of anti-gram-positive resistant organism or its preparation method, and the antibacterial combination that contains them; Specifically, relate to 7-[(3-methyl-) 3-aminomethyl-4-(fluorine methoxyimino)-tetramethyleneimine-1-yl] naphthyridon carboxylic acid compounds or its preparation method.
Background technology
From Nalidixic Acid (nalidixic acid in 1962; J.Med.Chem.1962; 5:1063) since the appearance; Quinolone (comprising a naphthyridines ketone) type medicine developed into the one type of wide spectrum that is only second to cynnematin at present, efficient, hypotoxic anti-infective chemotherapeutics (Chinese Journal of Pharmaceuticals 2010,41:456).Owing to be widely used and non-rational use of drug; Bacterium increases sharply to the resistance of this type medicine; Especially the continuous appearance of Pseudomonas aeruginosa in the gram-negative bacteria and the methicillin-resistant in gram positive organism gold Portugal bacterium (MRSA), methicillin-resistant form staph (MRSE), vancomycin-resistant enterococcus (VRE) and penicillin resistant streptococcus pneumoniae (PRSP) infection has become one of thorny problem that the clinicist faces.People press for and search out the Novel Quinolone class antimicrobial drug stronger to these resistant organism activity, to tackle these increasing drug-fast bacteria infections.
Nineteen ninety-five; Sanchez etc. have reported that the 7-position has five, the active (J.Med.Chem.1995 of synthetic and external biological of hexa-atomic nitrogen heterocyclic ring substituent a series of (5-amino-) 8-alkoxyl group fluoroquinolone compounds; 38:4478), wherein representative 7-(3-aminomethyl pyrrolidine-1-yl)-8-methoxy fluoroquinolone shows broad spectrum antibiotic activity.
Nineteen ninety-five, Chinese patent (CN:95107008.8 1995-06-15) discloses the fluoroquinolone compound with following general formula [A]:
Figure BDA0000077666820000011
And the substituent R in the mutual-through type 2Carried out definition widely, but R 2Do not comprise a methyl fluoride or difluoromethyl.
The outstanding representative of general formula [A] is to have succeeded in developing and by the FDA approval SB 265805 (gemifloxacin) in U.S.'s listing; It is except having broad spectrum of activity; Its outstanding advantage is other Comprecins that the activity to streptococcus pneumoniae is superior to having gone on the market; Its shortcoming is not strong to common clinically golden Portugal bacterium (comprising increasing MRSA) activity, thereby has limited its range of application clinically.
Nineteen ninety-five, Korean Patent 024002 (1995-08-31) discloses the fluoroquinolone compound with following general formula [B]:
Figure BDA0000077666820000021
And the substituent R in the mutual-through type 2Carried out definition widely, but R 2Do not comprise a fluorine-based or difluoromethyl.
The outstanding representative DW286 of general formula [B] is weaker than SB 265805 to the activity of gram-negative bacteria, but the activity of anti-gram positive organism is superior to SB 265805.It is reported that DW286 has stopped further research and development after accomplishing the I clinical trial phase.Agnogenio.
In order to overcome above-mentioned existing in prior technology defective, the inventor has carried out extensive studies, and design has been synthesized the 7-position and had the substituted tetramethyleneimine of one fluorine/difluoro methoxyimino-1-base naphthyridon carboxylic acid compounds, and has measured their anti-microbial activity.The final discovery; The 7-of bibliographical information different from the past [(3-methyl)-3-aminomethyl-4-(one fluorine/difluoro methoxyimino)-tetramethyleneimine-1-yl] naphthyridon carboxylic acid compounds has beyond thought strong anti-microbial activity to clinical important pathogenic bacteria; Compare with the carbostyril family antibacterial drugs that has gone on the market; It significantly has more superior anti-microbial activity; Especially be 2-＞521 times of contrast medicine CIPROFLOXACIN USP 24 to the external activity that comprises the golden Portugal bacterium of MRSA, the form staph that comprises MRSE and Pseudomonas aeruginosa, the 2-32 of SB 265805 doubly; To the activity in vivo of the golden bacterium MRSA10-2 of Portugal, form staph MRSE10-4 and Pseudomonas aeruginosa 10-1 be CIPROFLOXACIN USP 24 and SB 265805 1.4-6.1 doubly.
Summary of the invention
The purpose of this invention is to provide one type by the naphthyridon carboxylic acid compounds of general formula (I) expression or its pharmaceutical salts, hydrate,
Figure BDA0000077666820000031
Wherein:
R represents cyclopropyl, 2,4 difluorobenzene base;
R 1Represent H, CH 3
R 2Represent CH 2F, CHF 2
X represents H, F.
In the pyrrolidyl of general formula of the present invention (I) compound part, the carbon atom that links to each other with aminomethyl is a unsymmetrical carbon, therefore can R or S or R and the existence of S blended form, the present invention includes all these isomer and mixture.
In the pyrrolidyl part of general formula of the present invention (I) compound; Because the existence of 4-position oximido; Therefore general formula (I) compound can the E type or the form existence of Z type or E type and Z type mixture, and general formula of the present invention (I) compound comprises all these isomer and mixture.
Formula of the present invention (I) compound in pharmaceutically acceptable atoxic pharmaceutical salts; Comprise and mineral acid that the salt that example hydrochloric acid, sulfuric acid form is with organic acid; Salt like acetate, trifluoroacetic acid, Hydrocerol A, toxilic acid, oxalic acid, succsinic acid, phenylformic acid, tartrate, fumaric acid, racemic melic acid, xitix or oxysuccinic acid formation; And amino acid, the salt that forms like L-Ala, aspartic acid, Methionin or and sulfonic acid, the salt that forms like methylsulfonic acid, tosic acid.
Formula of the present invention (I) compound also can solvolyte (like hydrate) form exist, therefore, these solvolytes (like hydrate) are also included within the compound of the present invention.
The present invention specifically comprises following compound, and their pharmaceutical salts, hydrate:
1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
The invention still further relates to the preparation method of formula (I) compound, shown in reaction scheme 1.
Reaction scheme 1:
Figure BDA0000077666820000041
In reaction scheme 1, R, R 1, R 2With X such as aforesaid definition; R 3Represent alkyl or aromatic base, be preferably phenyl.
Comprise the steps:
1) in non-proton dipole solvent, add alkali, in room temperature to 100 ℃, formula (II) compound, formula (III) compound and formula (IV) compound carried out condensation reaction 0.5～10 hour, the formula V compound.
Figure BDA0000077666820000051
Wherein:
R, R 1, R 2, R 3With X such as aforesaid definition.
This reaction is generally carried out in the presence of alkali.Under this situation, in order to improve the reaction efficiency of more expensive formula (III) compound, use excessive reactant formula (II) compound and (IV) compound, for example to relative initiator for waiting mole to 5 times of molar weights, preferred equimolar amount to 2 times molar weight.When using excess reactant formula (II) compound with (IV) compound, the unreacted mixture that stays after the reaction is recyclable and be reused for reaction.The non-proton dipole solvent that is used for this reaction is selected from N, dinethylformamide, DMAC N,N, DMSO 99.8MIN. or acetonitrile; Described alkali is selected from triethylamine, yellow soda ash, sodium hydrogencarbonate, salt of wormwood, sodium hydroxide or Pottasium Hydroxide.
2) place protonic solvent to add acid the formula V compound then, in room temperature to 60 ℃, stirring reaction 2～30 hours is removed blocking group, formula (I) compound.Be used for this reaction protonic solvent be selected from water, alcohol or alcohol-water mixed solvent; Described acid is selected from methylsulfonic acid, hydrochloric acid, trifluoracetic acid.
When 3) needing, formula (I) compound that obtains is converted into its pharmaceutical salts or hydrate.
Formula (II) compound as initiator is a known compound in the present invention, and can easily make by known method in the existing publication.For example: J.Med.Chem.1991,34,1142; US4704459; US5457104 etc.
Be chemical reagent commonly used as formula (IV) compound of initiator in the present invention, domestic have a supply of commodities.
According to the method shown in the reactions route 2, can prepare another initiator formula (III) compound of the present invention.
Reaction scheme 2:
Figure BDA0000077666820000061
In reaction scheme 2, R 1And R 2Like aforesaid definition.
Method shown in the following specific explanations reaction scheme 2.
N-Boc-3-cyanic acid-4-pyrrolidone (1) selective catalytic hydrogenation in the presence of Pd/C protects corresponding aminomethyl to get compound 2 with Boc subsequently, and the latter gets tetramethyleneimine oximate thing 3 (R with oxammonium hydrochloride generation condensation reaction in the presence of alkali (like pyridine, triethylamine) 1=H).On the other hand, 1 earlier gets methide 4 with methyl iodide generation nucleophilic substitution reaction, then successively through selective catalytic hydrogenation and with Boc protection aminomethyl get compound 5 and with the oxammonium hydrochloride generation condensation reaction oxime compounds 3 (R that must methylate 1=CH 3).Then 3 with fluorine monobromethane or freonll-11 (difluorochloromethane) substitution reaction take place and obtain one fluorine/difluoro methoxyimino tetramethyleneimine 6, remove two Boc down in acid (like methylsulfonic acid, hydrochloric acid, trifluoracetic acid) at last and protect basicly, promptly get formula (III) compound.
In reaction scheme 2, the compound 1 that is used as initiator is a known compound, and can easily make by known method in the existing publication.Q.Guo etc. for example, Eur.J.Med.Chem.2010,45:5498; Wan Zhilong etc., Chinese pharmaceutical chemistry magazine 2009,19:109.
For the The compounds of this invention of R or S configuration, can adopt this area routine techniques to split, or carry out with the raw material of corresponding configuration that hand-type is synthetic to be obtained.
The present invention also provides and contains as above defined formula (I) compound, or its pharmaceutical salts or its hydrate are as the antibacterial combination of activeconstituents.
The weight ratio of naphthyridon carboxylic acid compounds in compsn that pharmaceutical composition contains is 0.1～99.9%, and the weight ratio of medicine acceptable carrier in compsn is 0.1～99.9%.Pharmaceutical composition exists to be fit to medicinal dosage form.Medicinal preparation is tablet, capsule, granule, pill, powder, paste, suspensoid, injection, powder injection, suppository, creme, drops or patch.Wherein, said tablet is sugar coated tablet, film coated tablet, enteric coated tablet or slow releasing tablet; Said capsule is hard capsule, soft capsule, slow releasing capsule; Said powder injection is a lyophilized injectable powder.
Pharmaceutical composition of the present invention, as dosage form, the significant quantity of the invention compound that contains in every dose is 0.1～1000mg; Said every dose refers to, and each preparation unit is like every of tablet; Capsular every, also can refer to each taking dose, as take 100mg at every turn.
But pharmaceutical composition of the present invention can use solid carrier when solid that is prepared into pulvis, tablet dispersion powder, capsule, cachet, suppository and ointment or semisolid pharmaceutical formulation.Spendable solid carrier is preferably one or more materials that are selected from thinner, seasonings, solubilizing agent, lubricant, suspension agent, tackiness agent, the swelling agent etc., or can be encapsulating substance.In powderous preparations, in carrier, contain 5～70% micronize activeconstituents.Suitable solid carrier comprises magnesiumcarbonate, Magnesium Stearate, talcum powder, sucrose, lactose, pectin, dextrin, starch, gelatin, methylcellulose gum, Xylo-Mucine, lower boiling wax, theobroma oil etc.Because they are easy to administration, tablet, the best oral solid formulation of representative such as pulvis, cachet and capsule.
Liquid preparation of the present invention comprises solution, suspension and emulsion.For example, the injection formulations of parenteral administration can be water or water-propylene glycol solution form, regulates its degree of oozing such as grade, and pH etc. make the physiological condition that is suitable for live body.Liquid preparation also can be made into the solution form in polyoxyethylene glycol, the aqueous solution.Can add an amount of tinting material, seasonings, stablizer and thickening material again through activeconstituents is dissolved in the water, prepare oral aqueous solution.Can micronized activeconstituents be dispersed in to prepare in viscous substance such as natural and synthetical glue, methylcellulose gum, Xylo-Mucine and other the known suspension agent and be suitable for oral aqueous suspensions.
In order to be easy to administration and dosage homogeneous, it is particularly advantageous that the said medicine preparation is mixed with dosage unit form.The dosage unit form of preparation refers to be suitable for the physical sepn unit as single dose, and each unit contains the activeconstituents of the good predetermined amount of the calculating that produces desired result of treatment.This dosage unit form can be packaged form, as tablet, capsule be contained in tubule or bottle in pulvis, be contained in the pipe or the bottle in ointment, gel or creme.
Though the amount of contained activeconstituents can change in the dosage unit form, generally, be adjusted in 1～800mg scope according to the effectiveness of selected activeconstituents.
When formula of the present invention (I) active compound is used as the medicine of treatment infectation of bacteria, preferably give the amount of 6～14mg/kg body weight in the fs.But dosage can change along with the seriousness of the infection of patient's needs, desire treatment, selected compounds etc.
Those skilled in the art can confirm to be suitable for the preferred dose of certain situation by ordinary method.Generally, the amount of begin treatment is lower than the optimal dose of activeconstituents, increases dosage then gradually, up to reaching optimum therapeuticing effect.For treatment needs, but total per daily dose single administration or branch administration for several times.
As stated; The compounds of this invention has beyond thought strong anti-microbial activity to important clinical bacteria; Compare with the carbostyril family antibacterial drugs that has gone on the market; It significantly has more superior anti-microbial activity, is 2-＞521 times of contrast medicine CIPROFLOXACIN USP 24 to the external activity that comprises the golden Portugal bacterium of MRSA, the form staph that comprises MRSE and Pseudomonas aeruginosa especially, and the 2-32 of SB 265805 doubly; To the activity in vivo of the golden bacterium MRSA10-2 of Portugal, form staph MRSE10-4 and Pseudomonas aeruginosa 10-1 be CIPROFLOXACIN USP 24 and SB 265805 1.4-6.1 doubly.
Embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.
Embodiment 1 1-(N-Boc)-4-(N-Boc) aminomethyl-tetramethyleneimine-3-ketone
With 1-(N-Boc)-4-cyanic acid-tetramethyleneimine-3-ketone (42.0g, 0.2mol) with (Boc) 2O (43.6g; 0.2mol) be dissolved in methyl alcohol (500mL), to wherein adding 5%Pd/C (8.2g), stirred overnight at room temperature under the 70ps i hydrogen pressure; Elimination Pd/C; Filtrate decompression concentrates, and resistates separates (with sherwood oil and ETHYLE ACETATE gradient elution) purifying through column chromatography, gets light yellow oil 31.5g (yield: 50%). 1H?NMR(DMSO-d 6，400MHz)δ ppm：6.98(1H，s)，3.80-2.79(7H，m)，1.42(9H，s)，1.38(9H，s)。ESI-MS(m/z)：315(M+H) +，337(M+Na) +。
Embodiment 2 1-(N-Boc)-3-(N-Boc) aminomethyl-4-hydroxyl imide base tetramethyleneimine
Under the room temperature, (41.7g, (40.2mL, 0.5mol), (94.2g, 0.3mol), equality of temperature stirs 1h to add embodiment 1 compound behind the stirring 10min to add pyridine in methanol solution 0.6mol) to oxammonium hydrochloride.Concentrating under reduced pressure, resistates is dissolved in ETHYLE ACETATE, uses 10% Glacial acetic acid min. 99.5, saturated sodium bicarbonate aqueous solution and water washing successively, anhydrous sodium sulfate drying.Filter, filtrate decompression concentrates, and to wherein adding sherwood oil (500mL), reflux is placed room temperature, has a large amount of solids to separate out.Filter, filter cake use petroleum ether, dry must white solid 80.0g (yield: 80%), mp:138-140 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：10.91(1H，s)，6.94(1H，s)，3.92-3.85(2H，m)，3.54-3.48(1H，m)，3.32-3.12(2H，m)，3.00-3.90(2H，m)，1.44(18H，s)。MS-ESI(m/z)：330(M+H) +。
Embodiment 3 1-(N-Boc)-4-methyl-4-Cyanopyrolidine-3-ketone
Under the room temperature, to 1-(N-Boc)-4-cyanic acid-tetramethyleneimine-3-ketone (21.0g, 0.1mol) and Anhydrous potassium carbonate (41.7g, (8.2mL 0.12mol), drip to finish (30min) equality of temperature and stirs 3h to drip methyl iodide in anhydrous propanone 0.3mol) (800mL) solution.Filter, filtrate decompression concentrates, and adds methylene dichloride (200mL) dissolving, washing (200mL * 3), concentrating under reduced pressure.In resistates, add sherwood oil (300mL), reflux 1h filters, after filter cake is washed with an amount of sherwood oil, and with the mixed solvent recrystallization of sherwood oil and ETHYLE ACETATE, must off-white color solid 18.8g (yield: 84%), mp:71-73 ℃. 1H?NMR(CDCl 3，400MHz)δ ppm：4.15-3.69(4H，m)，1.58(3H，s)，1.49(9H，s)。ESI-MS(m/z)：225(M+H) +。
Embodiment 4 1-(N-Boc)-4-methyl-4-(N-Boc) aminomethyl pyrrolidine-3-ketone
With embodiment 3 compounds (11.2g, 50mmol) with (Boc) 2O (10.9g 50mmol) is dissolved in the methyl alcohol (200mL), and adding Pd/C (5%, 2.0g), stirred overnight at room temperature under the 75psi hydrogen pressure.Elimination Pd/C, filtrate decompression concentrates, and adds sherwood oil (500mL) in the resistates, reflux 30min.After filtered while hot, filter cake are washed with sherwood oil, with the mixed solvent recrystallization of sherwood oil and ETHYLE ACETATE, off-white color solid 12.8g (yield: 78%), mp:106-108 ℃. 1H NMR (CDCl 3, 400MHz) δ Ppm: 4.77 (1H, brs), 3.83 (2H, s), 3.64-3.26 (4H, m), 1.50 (9H, s), 1.43 (9H, s), 1.15 (3H, s).ESI-MS(m/z)：329(M+H) +。
Embodiment 5 1-(N-Boc)-3-methyl-3-(N-Boc) aminomethyl-4-hydroxyl imide base tetramethyleneimine
Under the stirring at room, (2.5g, (2.4mL 30mmol), stirs 10min to add pyridine in methyl alcohol 36mmol) (100mL) solution to oxammonium hydrochloride.(10min drips complete for 9.8g, methyl alcohol 30mmol) (50mL), and equality of temperature stirs 1h in this solution, to drip embodiment 4 compounds.Concentrating under reduced pressure adds methylene dichloride dissolving (100mL), washing, anhydrous sodium sulfate drying in the resistates.Filter, filtrate decompression concentrates, and resistates adds sherwood oil (300mL), reflux 1h, and filtered while hot, filter cake is used ETHYLE ACETATE and petroleum ether respectively, dry off-white color solid 9.5g (yield: 93%), mp:149-150 ℃. 1H?NMR(CDCl 3，400MHz)δ ppm：10.86(1H，brs)，6.94(1H，brs)，3.96(2H，s)，3.50-2.98(4H，m)，1.40(9H，s)，1.36(9H，s)，1.06(3H，s)。ESI-MS(m/z)：344(M+H) +，366(M+Na) +。
Embodiment 6 1-(N-Boc)-3-methyl-3-(N-Boc) aminomethyl-4-one fluorine methoxy imino tetramethyleneimine
Under the stirring at room, to embodiment 5 compounds (3.4g, 10mmol) and Tetrabutyl amonium bromide (0.6g; Toluene 2mmol) (100mL) solution adds the 50%NaOH aqueous solution of 8 times of molar weights; (1.2g, 11mmol), equality of temperature stirred 5 hours to feed the fluorine monobromethane in the stirring downhill reaction mixture.Tell organic layer, washing, anhydrous sodium sulfate drying.Filter, filtrate decompression concentrates, and gets colorless oil 3.8g (quantitatively). 1H?NMR(CDCl 3，400MHz)δ ppm：7.08(1H，br?s)，5.66(2H，t，J＝56.0Hz)，4.09(2H，s)，3.53-2.97(4H，m)，1.40(9H，s)，1.36(9H，s)，1.09(3H，s)。ESI-MS(m/z)：376(M+H) +。
Embodiment 7 1-(N-Boc)-3-(N-Boc) aminomethyl-4-one fluorine methoxy imino tetramethyleneimine
With the preparation method of embodiment 6 compounds, embodiment 2 compounds and fluorine monobromethane react colorless oil (quantitatively). 1H?NMR(400MHz，DMSO-d 6)δ ppm：7.07(1H，br?s)，5.68(2H，d，J＝56Hz)，4.05(2H，brs)，3.57(1H，brs)，3.31-3.27(1H，m)，3.19(1H，brs)，3.10-3.03(2H，m)，1.45(9H，s)，1.40(9H，s)。MS-ESI(m/z)：362.2(M+H) +。
Embodiment 8 1-(N-Boc)-3-(N-Boc) aminomethyl-4-difluoro methoxy imino tetramethyleneimine
Under the stirring at room; To embodiment 2 compounds (6.6g, 20mmol) and Tetrabutyl amonium bromide (1.2g, toluene 4mmol) (150mL) solution add the 50%NaOH aqueous solution of 8 times of molar weights; Stir in the downhill reaction mixture and feed freonll-11 (F2CHCl) gas, 80 ℃ were stirred 10 hours.Tell organic layer, washing, anhydrous sodium sulfate drying.Filter, filtrate decompression concentrates, and silica gel column chromatography gets colorless oil 2.27g (yield: 30%). 1H?NMR(400MHz，DMSO-d 6)δ ppm：7.07(1H，brs)，7.06(1H，t，J＝72Hz)，4.09(2H，brs)，3.58(1H，brs)，3.32-3.28(1H，m)，3.20(1H，brs)，3.11-3.07(2H，m)，1.41(9H，s)，1.37(9H，s)。MS-ESI(m/z)：380.4(M+H) +。
Embodiment 9 3-aminomethyl-4-one fluorine methoxy imino-tetramethyleneimine dimethanesulfonate
Under the stirring at room, (7.2g, (5.76g, 60mmol), equality of temperature stirs 24h to add methylsulfonic acid in methyl alcohol 20mmol) (50mL) solution to embodiment 7 compounds.The solid that filtration is separated out, vacuum-drying, white solid 4.94g (yield: 70%), mp:137-139 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：9.32(2H，brs)，7.99(3H，brs)，5.74(2H，d，J＝56Hz)，4.16-3.99(2H，m)，3.75-3.71(1H，m)，3.36-3.28(2H，m)，3.19-3.07(2H，m)，2.38(6H，s)。MS-ESI(m/z)：162.1(M+H) +。
(0.36g, absolute anhydrous methanol (6mL) solution 1mmol) fully stir down 3-methyl-4-one fluorine methoxy imino tetramethyleneimine dimethanesulfonate, and (0.08g, 2mmol), equality of temperature continues to stir 0.5 hour the sodium hydroxide of 2 times of molar weights of adding.Concentrating under reduced pressure, resistates get 3-methyl-4-fluorine methoxy imino tetramethyleneimine 0.33g (yield: 95%) through column chromatographic isolation and purification.
Also can prepare following salt similarly, for example:
3-methyl-4-one fluorine methoxy imino-tetramethyleneimine dihydrochloride;
3-methyl-4-one fluorine methoxy imino-tetramethyleneimine two (trifluoro) acetate.
Embodiment 10 3-aminomethyl-4-difluoro methoxy imino tetramethyleneimine dimethanesulfonate
With the preparation method of embodiment 9 compounds, embodiment 8 compounds and methylsulfonic acid react white solid (yield: 90%), mp:168-170 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：9.35(2H，brs)，7.97(3H，brs)，7.16(1H，t，J＝72Hz)，4.22-4.05(2H，m)，3.77-3.73(2H，m)，3.45-3.40(1H，m)，3.16-3.12(2H，m)，2.37(6H，s)。MS-ESI(m/z)：180.2(M+H) +。
Embodiment 11 3-methyl-3-aminomethyl-4-one fluorine methoxy imino tetramethyleneimine dimethanesulfonate
With the preparation method of embodiment 9 compounds, embodiment 6 compounds and methylsulfonic acid react white solid (yield: 86%). 1H?NMR(400MHz，DMSO-d 6)δ ppm：9.32(2H，brs)，7.58(3H，brs)，5.70(2H，t，J＝56.0Hz)，4.09(2H，s)，3.77-3.05(4H，m)，2.37(6H，s)，1.09(3H，s)。MS-ESI(m/z)：176.2(M+H) +。
Embodiment 12 1-cyclopropyl-6-fluoro-7-[3-Ben Yajiaji aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
Under nitrogen protection and the stirring at room, to embodiment 9 compounds (35.34g, add in anhydrous acetonitrile 0.1mol) (500mL) suspension liquid exsiccant triethylamine (115mL, 0.8mol) and phenyl aldehyde (12mL, 0.12mol), equality of temperature stirs 1h.To wherein adding 1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-1, (25g, 0.09mol), equality of temperature continues stirred overnight to 8-naphthyridines-3-carboxylic acid.The solid that filtration is separated out, acetonitrile wash white solid 39.6g (yield: 80%), mp:176-178 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.22(1H，s)，8.53(1H，s)，8.38(1H，s)，7.91(1H，d，J＝13Hz)，7.58(2H，d，J＝8Hz)，7.36-7.27(3H，m)，5.77(2H，d，J＝56Hz)，4.71-4.62(2H，m)，4.13-4.09(2H，m)，3.93-3.85(2H，m)，3.67-3.62(1H，m)，3.52-3.49(1H，m)，1.13-0.99(4H，m)。MS-FAB(m/z)：496.9(M+H) +。
Also can prepare following compound similarly, for example:
1-cyclopropyl-6-fluoro-7-[3-p-nitrophenyl methylene radical aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-[3-second subunit aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
Embodiment 13 1-cyclopropyl-7-[3-Ben Yajiaji aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 9 compounds and 1-cyclopropyl-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction gets white solid (yield: 76%). 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.20(1H，s)，8.54(1H，s)，8.36(1H，s)，7.65-7.59(2H，m)，7.54(2H，d，J＝8Hz)，7.36-7.27(3H，m)，5.77(2H，d，J＝56Hz)，4.70-4.65(2H，m)，4.12-4.09(2H，m)，3.93-3.85(2H，m)，3.67-3.63(1H，m)，3.48-3.43(1H，m)，1.13-0.99(4H，m)。MS-FAB(m/z)：478.25(M+H) +。
Embodiment 14 1-(2,4 difluorobenzene base)-6-fluoro-7-[3-Ben Yajiaji aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 9 compounds and 1-(2,4 difluorobenzene base)-6-fluoro-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction get white solid (yield: 70%) mp:248-250 ℃. 1H?NMR(400MHz，CDCl 3)δ ppm：14.74(1H，s)，8.64(1H，s)，8.27(1H，s)，8.08(1H，d，J＝13Hz)，7.66-7.52(2H，m)，7.43-7.32(4H，m)，7.03-6.99(2H，m)，5.61(2H，d，J＝56Hz)，4.46-3.36(7H，m)。MS-ESI(m/z)：568.4(M+H) +。
Embodiment 15 1-cyclopropyl-6-fluoro-7-[3-Ben Yajiaji aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 10 compounds and 1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction get white solid (yield: 76%), mp:205-207 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.19(1H，br?s)，8.55(1H，s)，8.39(1H，s)，7.94(1H，d，J＝13Hz)，7.58(2H，d，J＝8Hz)，7.36-7.27(3H，m)，7.16(1H，t，J＝72Hz)，4.77-4.70(2H，m)，4.20-4.13(2H，m)，3.91-3.89(2H，m)，3.68-3.62(1H，m)，3.59-3.56(1H，m)，1.14-1.00(4H，m)。MS-FAB(m/z)：514.2(M+H) +。
Embodiment 16 1-(2,4 difluorobenzene base)-6-fluoro-7-[3-Ben Yajiaji aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 10 compounds and 1-(2,4 difluorobenzene base)-6-fluoro-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction gets white solid (yield: 70%). 1H?NMR(400MHz，CDCl 3)δ ppm：14.96(1H，s)，8.88(1H，s)，8.19(1H，d，J＝13Hz)，7.92-7.78(4H，m)，7.58(3H，m)，7.36-7.27(4H，m)，7.14(1H，t，J＝72Hz)，4.46-4.00(3H，m)，3.92-3.60(1H，m)，3.53-3.40(1H，m)，3.18-3.03(2H，m)，2.29(3H，s)。MS-FAB(m/z)：586.2(M+H) +。
Embodiment 17 1-cyclopropyl-6-fluoro-7-[3-methyl-3-Ben Yajiaji aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 11 compounds and 1-cyclopropyl-6-fluoro-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction gets off-white color solid (yield: 75%). 1H?NMR(400MHz，CDCl 3)δ ppm：8.58(1H，s)，8.03(1H，d，J＝12.8Hz)，7.58(2H，m)，7.36-7.27(3H，m)，5.76(2H，d，J＝64Hz)，4.71(2H，s)，4.28(1H，d，J＝11.2Hz)，3.75-3.71(2H，m)，3.31(2H，s)，2.73(2H，q，J＝12.8Hz)，1.25(3H，s)，1.22-1.17(2H，m)，1.12-1.09(2H，m)。MS-FAB(m/z)：510.2(M+H) +。
Embodiment 18 1-cyclopropyl-7-[3-methyl-3-Ben Yajiaji aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 12 compounds, embodiment 11 compounds and 1-cyclopropyl-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction gets off-white color solid (yield: 78%). 1H?NMR(400MHz，CDCl 3)δ ppm：8.58(1H，s)，7.36-7.27(3H，m)，7.36-7.58(4H，m)，7.36-7.27(3H，m)，5.76(2H，d，J＝64Hz)，4.71(2H，s)，4.28(1H，d，J＝11.2Hz)，3.75-3.71(2H，m)，3.31(2H，s)，2.73(2H，q，J＝12.8Hz)，1.25(3H，s)，1.22-1.17(2H，m)，1.12-1.09(2H，m)。MS-FAB(m/z)：492.2(M+H) +。
Embodiment 19 1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid mesylate
Under the stirring at room, to embodiment 12 compounds (29.7g, add in ethanol 60mmol) (500mL) solution methylsulfonic acid (5.76g, 60mmol), water (5mL), equality of temperature stirs 24h.The solid that filtration is separated out, vacuum-drying, white solid 19.6g (yield: 80%), mp:220-222 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.22(1H，brs)，8.60(1H，s)，8.08(1H，d，J＝13Hz)，7.95(3H，brs)，5.79(2H，d，J＝56Hz)，4.71-4.64(2H，m)，4.44-4.39(1H，m)，3.88-3.83(1H，m)，3.74-3.68(1H，m)，3.52-3.49(1H，m)，3.20-3.14(2H，m)，2.31(3H，s)，1.24-1.02(4H，m)。MS-FAB(m/z)：408.4(M+H) +.HRMS-FAB：m/z?Calcd.for?C 18H 20N 5O 4F 2(M+H) +：408.1483。
Embodiment 20 1-cyclopropyl-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid mesylate
With the preparation method of embodiment 19 compounds, embodiment 13 compounds and 1-cyclopropyl-7-chloro-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid reaction get white solid (yield: 58%), mp:＞240 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.43(1H，s)，8.59(1H，s)，8.34(1H，brs)，7.95(3H，brs)，6.93(1H，brs)，5.80(2H，d，J＝56Hz)，4.61-4.40(2H，m)，4.29-4.00(1H，m)，3.80-3.08(5H，m)，2.31(3H，s)，1.22-1.06(4H，m)。MS-ESI(m/z)：390.2(M+H) +。
Embodiment 21 1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid mesylate
With the preparation method of embodiment 19 compounds, embodiment 14 compounds and methylsulfonic acid react white solid (yield: 68%), mp:168-170 ℃. 1H?NMR(400MHz，DMSO-d 6)δ ppm：8.84(1H，s)，8.17(1H，d，J＝13Hz)，7.86-7.78(4H，m)，7.59-7.56(1H，m)，7.36-7.32(1H，m)，5.72(2H，d，J＝56Hz)，4.46-3.90(3H，m)，3.72-3.30(2H，m)，3.20-3.00(2H，m)，2.32(3H，s)。MS-FAB(m/z)：480.1(M+H) +。HRMS-FAB：m/z?Calcd.for?C 21H 18N 5O 4F 4(M+H) +：480.1295。
Embodiment 22 1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid mesylate
With the preparation method of embodiment 19 compounds, embodiment 15 compounds and methylsulfonic acid react white solid (yield: 65%).mp：235-237℃。 1H?NMR(400MHz，DMSO-d 6)δ ppm：15.19(1H，brs)，8.59(1H，s)，8.08(1H，d，J＝13Hz)，8.00(3H，brs)，7.18(1H，t，J＝72Hz)，4.77-4.66(2H，m)，4.46-4.41(1H，m)，3.91-3.87(1H，m)，3.74-3.68(1H，m)，3.61-3.53(1H，m)，3.45-3.41(1H，m)，3.22-3.20(1H，m)，2.32(3H，s)，1.24-1.02(4H，m)。MS-FAB(m/z)：426.1(M+H) +。HRMS-ESI：m/z?Calcd.for?C 18H 19N 5O 4F 3(M+H) +：426.1404。
Embodiment 23 1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid mesylate
With the preparation method of embodiment 19 compounds, embodiment 16 compounds and methylsulfonic acid react white solid (yield: 50%).mp：145-147℃。 1H?NMR(400MHz，DMSO-d 6)δ ppm：14.96(1H，s)，8.88(1H，s)，8.19(1H，d，J＝13Hz)，7.92-7.78(4H，m)，7.58-7.51(1H，m)，7.36-7.32(1H，m)，7.10(1H，t，J＝72Hz)，4.46-4.00(3H，m)，3.92-3.60(1H，m)，3.53-3.40(1H，m)，3.18-3.03(2H，m)，2.29(3H，s)。MS-FAB(m/z)：498.0(M+H) +。HRMS-FAB：m/z?Calcd.for?C 21H 17N 5O 4F 5(M+H) +：498.1201。
Embodiment 24 1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
Preparing method with embodiment 19 compounds; Embodiment 17 compounds (0.51g, 1mmol) accomplish with methylsulfonic acid reaction after, with 1N sodium hydroxide solution accent pH=7; Evaporated under reduced pressure; Resistates separates through silicagel column (with methylene dichloride and methyl alcohol gradient elution), white solid 0.41g (yield: 97.6%), mp:195 ℃. 1H?NMR(DMSO-d 6，400MHz)δ ppm：8.58(1H，s)，8.03(1H，d，J＝12.8Hz)，5.76(2H，d，J＝64Hz)，4.71(2H，s)，4.28(1H，d，J＝11.2Hz)，3.75-3.71(2H，m)，3.31(2H，s)，2.73(2H，q，J＝12.8Hz)，1.25(3H，s)，1.22-1.17(2H，m)，1.12-1.09(2H，m)。ESI-MS(m/z)：422(M+H) +。HRMS-ESI(m/z)：C 19H 22F 2N 5O 4，Calcd：422.1640；Found?422.1656。
C 19H 21F 2N 5O 4 C H N F
Calculated value 54.15 5.02 16.62 9.02
Measured value 54.18 5.00 16.60 8.99
Embodiment 25 1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid monohydrate
(0.42g 1mmol) is dissolved in 5% acetic acid (8mL), under the stirring at room, transfers pH=7 with the 1N sodium hydroxide solution, places and separates out solid with embodiment 24 compounds.Filter, drying gets 1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid monohydrate 0.35g (off-white color solid, yield: 80%).
C 19H 21F 2N 5O 4 ·H 2O C H N F
Calculated value 51.93 5.28 15.94 8.65
Measured value 51.90 5.29 15.93 8.67
Embodiment 26 1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid hydrochloride
Under the refluxing and stirring, (add the 6N hydrochloric acid (dissolving clear) of 1.5 times of molar weights among the 0.42g, absolute absolute ethyl alcohol suspension liquid (20mL) 1mmol), continue to stir 0.5 hour, reduce to room temperature, separate out solid to embodiment 24 compounds.Filter, drying gets 1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid hydrochloride 0.42g (off-white color solid, yield: 92%).
C 26H 28FN 5O 6 ·HCl C H N F Cl
Calculated value 55.57 5.20 12.46 3.38 6.31
Measured value 55.62 5.21 12.37 3.39 6.30
Also can prepare following salt similarly, for example:
1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid lactic acid salt;
1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid tosilate.
Embodiment 27 1-cyclopropyl-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
With the preparation method of embodiment 24 compounds, by embodiment 18 compounds can get white solid (yield: 100%), mp:184-186 ℃. 1H?NMR(DMSO-d 6，400MHz)δ ppm：8.57(1H，s)，8.29(1H，s)，6.94(1H，s)，5.76(2H，d，J＝65.6Hz)，4.53(2H，s)，4.14-4.02(1H，m)，3.77-3.71(1H，m)，3.58-3.31(1H，m)，2.70(2H，q)，1.25(3H，s)，1.20-1.12(2H，m)，1.09-1.03(2H，m)。ESI-MS(m/z)：404(M+H) +。HRMS-ESI(m/z)：C 19H 23FN 5O 4，Calcd：404.1734；Found?404.1739。
Embodiment 28
Coating tablet
The label prescription:
Figure BDA0000077666820000171
Figure BDA0000077666820000181
Get mentioned component and mix, the whole grain that sieves after the granulation, dry, compressing tablet is processed 100 labels.
Coating fluid prescription:
Opadry (Opadry) 5g, an amount of dressing of 80% ethanol.
Embodiment 29 capsules
Prescription:
Figure BDA0000077666820000182
The preparation method:
Get the recipe quantity supplementary material, sieve respectively, add 5% Vinylpyrrolidone polymer alcohol liquid and tween 80 system softwood; Granulate with 20 mesh sieves, under 15 ℃ of room temperatures, dry, add sodium lauryl sulphate; Mix, by the 0.27g/S gastric-dissolved capsule of packing into No. 0, sample examination; The stripping limit is Q=80%, and content should be the 90-110% of labelled amount.
The preparation of embodiment 30 injections
Get 1 gram embodiment, 27 compounds, add an amount of water for injection and make dissolving, add poloxamer 10 grams, add sodium-chlor 4 grams; DEXTRAN 500.000 10 grams add glucose 4 grams, N.F,USP MANNITOL 5 grams; Mix, add water for injection to 1000 milliliter, process 10 bottles of intravenous injections.
Experimental example 1
This experimental example is to study the antibacterial activity in vitro of The compounds of this invention.
The anti-microbial activity of The compounds of this invention is that (MIC mg/L) realizes to the minimum inhibitory concentration of reference culture, clinical isolates strain through measuring it.Minimum inhibitory concentration is measured as follows: adopt plate doubling dilution and Denlay multiple spot inoculator to carry out drug sensitive experiment, experimental bacteria increases bacterium with nutrient broth and angry heart immersion liquid; Become various desired concns with the doubling dilution of MH meat soup behind the medicine dissolution; Add respectively in right amount in plate; The MH nutrient agar dissolves quantitative injection the in back and contains mixing in the soup plate; The final concentration of medicine is respectively 0.008,0.015,0.03,0.06,0.125......128 μ g/mL, in the plate after the culture medium solidifying with multiple spot inoculator inoculation experiments bacterium (10 5The cfu/ point), put 35 ℃ of constant temperature culture observations after 18 hours, the minimum concentration of contained drug is minimum inhibitory concentration (MIC) in the plate of asepsis growth.
Table 1 has been listed some representation compounds in the application's formula (I) compound to the antibacterial activity in vitro of some important clinical pathogenic strainss, and with clinical widely used outstanding fluoroquinolone antibacterial agent CIPROFLOXACIN USP 24 at present and recently the SB 265805 of new listing compare.
Table 1 embodiment 21 and 23 compounds are to the antibacterial activity in vitro of gram positive organism
Figure BDA0000077666820000191
Visible by table 1; Embodiment 21 compounds in the application's formula (I) compound and embodiment 23 compounds are 2-＞521 times of CIPROFLOXACIN USP 24 to the activity that comprises the golden Portugal bacterium of MRSA, the form staph that comprises MRSE and Pseudomonas aeruginosa, and the 2-32 of SB 265805 doubly.
Experimental example 2
This experimental example is to study the antibacterial activity in vivo of The compounds of this invention.
All with the preparation of 0.9% saline water, the dose groups spacing is 1: 0.65～1: 0.8 in the test medication, and each compound is all established 5 dose groups.
Get healthy Kunming mouse, body weight 18～22g evenly divides into groups by sex, body weight at random, and 10 every group, male and female half and half are injected the infectious bacteria liquid of minimum lethal dose (1MLD) respectively, every mouse 0.5mL to mouse peritoneal.After the infection, contain the testing compound soup of different concns for respectively mouse oral administration gavage and intravenous injection, every each 0.5mL of mouse irritates stomach 1 time again behind the oral administration 4h, establish the infection control group simultaneously, and record infects dead mouse number in the 7d of back.Bliss method in experimental result utilization DAS 110 softwares is calculated median effective dose ED 50And 95% fiducial limit, and carry out statistical procedures.
Table 2 embodiment 19 and 20 compounds and the interior curative effect (ED of contrast medicine to the mouse peritoneal infection pathogen 50Mg/kg)
Figure BDA0000077666820000201
Figure BDA0000077666820000211
Visible by table 2, be contrast medicine SB 265805 and CIPROFLOXACIN USP 24 1.4-6.1 times to the interior curative effect of the golden bacterium MRSA10-2 of Portugal, form staph MRSE10-4 and Pseudomonas aeruginosa 10-1 when embodiment 19 and 20 compound oral administration gavage administrations.
The pharmacokinetics aspect of performance is compared with known fluoroquinolone compound, and The compounds of this invention has suitable water-soluble, therefore can be absorbed well in vivo, show very high bioavailability, the suitable antiseptic-germicide that is used as.
Experimental example 3
This experimental example is to study the oral acute toxicity of The compounds of this invention.
For measuring the oral acute toxicity of The compounds of this invention; Embodiment 22 compounds and embodiment 24 compounds have been carried out acute toxicity test; The oral male mice that awards of solution that will contain these two compounds of different concns; Dosage is the 0.1ml/10g body weight, and the dead mouse amount that counts respectively after 7 days is with the medium lethal dose(LD&-{50}) (LD of each compound of Bliss program calculating 50).The result lists in the table 3.
The oral acute toxicity of the mouse of table 5 experimental compound
Experimental compound LD 50(mg/kg)
Embodiment 22 ＞3000
Embodiment 24 ＞3000
Experimental result shows that these toxicity of compound are very low, is fit to very much medicinal.
Though, the present invention has been done detailed description in the preceding text with general explanation and specific embodiments, on basis of the present invention, can to some modifications of do or improvement, this will be apparent to those skilled in the art.Therefore, these modifications or the improvement on the basis of not departing from spirit of the present invention, made all belong to the scope that requirement of the present invention is protected.

Claims (10)

1. compound or pharmaceutically acceptable salt thereof, hydrate shown in the formula (I):
Figure FDA0000077666810000011
Wherein:
R represents cyclopropyl, 2,4 difluorobenzene base;
R 1Represent H, CH 3
R 2Represent CH 2F, CHF 2
X represents H, F.
2. compound or pharmaceutically acceptable salt thereof, hydrate is characterized in that shown in the formula according to claim 1 (I), and said compound is selected from:
1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl)]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-(2,4 difluorobenzene base)-6-fluoro-7-[3-aminomethyl-4-(difluoro methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid
1-cyclopropyl-7-[3-methyl-3-aminomethyl-4-(a fluorine methoxy imino)-tetramethyleneimine-1-yl]-1,4-dihydro-4-oxo-1,8-naphthyridines-3-carboxylic acid.
3. claim 1 or 2 any one compound or pharmaceutically acceptable salt thereof, hydrate is characterized in that, wherein pharmaceutical salts is the salt that forms with mineral acid or organic acid.
4. contain claim 1 or 2 any one compound or pharmaceutically acceptable salt thereof, medicinal compound of hydrate.
5. pharmaceutical composition according to claim 4 is characterized in that, said composition is tablet, capsule, granule, pill, powder, paste, suspensoid, injection, powder injection, suppository, creme, drops or patch.
6. pharmaceutical composition according to claim 5 is characterized in that, said tablet is sugar coated tablet, film coated tablet, enteric coated tablet or slow releasing tablet; Said capsule is hard capsule, soft capsule, slow releasing capsule; Said powder injection is a lyophilized injectable powder.
7. the midbody of preparation claim 1 compound or pharmaceutically acceptable salt thereof, hydrate is characterized in that, is compound shown in the formula (III) or its salt with hydrochloric acid, methylsulfonic acid, trifluoracetic acid formation
Figure FDA0000077666810000021
Wherein, R 1And R 2Definition with claim 1.
8. the preparation method of the said compound or pharmaceutically acceptable salt thereof of claim 1, hydrate is characterized in that, comprises the steps:
1) in non-proton dipole solvent, add alkali, in room temperature to 100 ℃, formula (II) compound, formula (III) compound and formula (IV) compound carried out condensation reaction 0.5～10 hour, the formula V compound.
2) place protonic solvent to add acid the formula V compound then, in room temperature to 60 ℃, stirring reaction 2～30 hours is removed blocking group, formula (I) compound.
Figure FDA0000077666810000031
Wherein:
R, R 1, R 2With the definition of X with claim 1;
R 3Represent alkyl or aromatic base.
9. preparation method according to claim 8 is characterized in that, described non-proton dipole solvent is selected from N, dinethylformamide, DMAC N,N, DMSO 99.8MIN. or acetonitrile; Described alkali is selected from triethylamine, yellow soda ash, sodium hydrogencarbonate, salt of wormwood, sodium hydroxide or Pottasium Hydroxide; Described protonic solvent is selected from water, alcohol or alcohol-water mixed solvent; Described acid is selected from methylsulfonic acid, hydrochloric acid, trifluoracetic acid.
10. compound or pharmaceutically acceptable salt thereof, hydrate is characterized in that shown in the formula according to claim 1 (I), are R or S configuration.
CN201110207280A 2011-07-22 2011-07-22 Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof Pending CN102329315A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110207280A CN102329315A (en) 2011-07-22 2011-07-22 Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110207280A CN102329315A (en) 2011-07-22 2011-07-22 Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof

Publications (1)

Publication Number Publication Date
CN102329315A true CN102329315A (en) 2012-01-25

Family

ID=45481302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110207280A Pending CN102329315A (en) 2011-07-22 2011-07-22 Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102329315A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103497186A (en) * 2013-09-24 2014-01-08 浙江司太立制药股份有限公司 Alcoxyimino-contained substituted naphthyridine-carboxylic acid derivatives and preparation method thereof
CN103922987A (en) * 2014-05-04 2014-07-16 苏州天马精细化学品股份有限公司 Zabofloxacin intermediate and synthetic method thereof.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114959A (en) * 1994-06-16 1996-01-17 Lg化学株式会社 Novel quinoline carboxylic acid derivatives having 7-(4-aminomethyl-3-oxime) pyrrolidine substituent and processes for preparing thereof
US20030050321A1 (en) * 1997-03-21 2003-03-13 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
CN101863876A (en) * 2010-04-23 2010-10-20 中国医学科学院医药生物技术研究所 Fluoroquinolone comprising 7-(3-amino-4-oximido)-1-piperidyl substitutional group and application of composition thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114959A (en) * 1994-06-16 1996-01-17 Lg化学株式会社 Novel quinoline carboxylic acid derivatives having 7-(4-aminomethyl-3-oxime) pyrrolidine substituent and processes for preparing thereof
US20030050321A1 (en) * 1997-03-21 2003-03-13 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
CN101863876A (en) * 2010-04-23 2010-10-20 中国医学科学院医药生物技术研究所 Fluoroquinolone comprising 7-(3-amino-4-oximido)-1-piperidyl substitutional group and application of composition thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
《Journal of Infection and Chemotherapy》 20021231 Takashi Ida et al., CP6679,a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa 138-144 1-10 第8卷, *
《中国医药工业杂志》 20100610 吕凯等， 喹诺酮抗肿瘤活性及构效关系研究进展 456-463 1-10 第41卷, 第6期 *
《中药学专业知识（一）》 20050630 国家执业药师资格考试指导丛书编委会 第十六章注射剂（附滴眼剂） 人民军医出版社 第312页和第316页 5-6 , *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103497186A (en) * 2013-09-24 2014-01-08 浙江司太立制药股份有限公司 Alcoxyimino-contained substituted naphthyridine-carboxylic acid derivatives and preparation method thereof
CN103497186B (en) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 Alcoxyimino-contained substituted naphthyridine-carboxylic acid derivatives and preparation method thereof
CN103922987A (en) * 2014-05-04 2014-07-16 苏州天马精细化学品股份有限公司 Zabofloxacin intermediate and synthetic method thereof.

Similar Documents

Publication Publication Date Title
AU2016287478B2 (en) Antibacterial compounds
US11179396B2 (en) Heterocyclic compounds as antibacterials
CA3025727A1 (en) Heterocyclic compounds as antibacterials
CN101553470A (en) Antibacterial quinoline derivatives
CN101070322A (en) 7-(4-nitroyl-3-amino-1-piperidyl) quinolinecarboxylic acid derivative, its preparing method and use
CN109942546B (en) Quinolone pyrimidine compound and preparation method and application thereof
CN100497331C (en) 7-(4-oxime-3-amino-1-piperidine) quinoline carboxylic acid derivative and method for making same
CN101547907A (en) Antibacterial quinoline derivatives
CN101298452A (en) Preparing methods and uses of S-(-)-nadifloxacin and water soluble salt thereof
EP1633363B1 (en) Pyridinyl acetonitriles
CN107698567A (en) Isatin azoles alcohol compound and preparation method thereof and medical applications
CN101679416B (en) Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3, 4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceu
CN102329315A (en) Fluoro methoxyimino-substituted nalidixic carboxylic acid compound and preparation method thereof
JPS62129273A (en) 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acids
CN102964350A (en) 7-hexahydropyrrolo[1, 2-a]pyrazinylquinolonecarboxylic acid derivative and its application in treatment of Helicobacter pylori infections
CN103483315B (en) 7-(3-aminomethyl-4-alkoxyimino-1-piperidyl)-1-[(1R,2S)-2-fluorocyclopropyl] quinolone carboxylic acid compounds and preparation method thereof
CN101450938B (en) 7-(4-oximido-3-amido-3-alkyl-1-piperidine)quinoline carboxylic acid derivates and preparation method thereof
CN103467448B (en) 7-(3-amino-4-alcoxylimido-1-piperidyl)-1-[(1R, 2S)-2-fluoro-cyclopropyl] quinolone carboxylic acid compounds and preparation methods thereof
CN104098588A (en) Tricyclic quinolone derivative, preparation method and application thereof
CN102321082A (en) Naphthyridinone carboxylic acid compound and preparation method thereof
US6822098B2 (en) Ester or amide derivatives
CN102060793B (en) Dual aryl tertiary amine azole compounds with biological activity as well as preparation method and medical application thereof
CN101450947B (en) 7-(3-oximido-4-amido-4-alkyl-1-piperidine)quinoline carboxylic acid derivates and preparation method thereof
US11945818B1 (en) Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
JP3796612B2 (en) Antibacterial agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120125